Aortic valve stenosis with osteoporosis
Conditions
Interventions
Treatment with risedronate and alfacalcidol
Treatment with alfacalcidol
Sponsors
Juntendo University School of Medcine, The department of Cardiology
Juntendo University School of Medcine, the department of orthopedic surgery
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. mild to moderate aortic valve stenosis or calcification on echocardiography without operative indication 2. postmenopausal women 3. patients in whom written informed consent was obtained after a detailed explanation of the study purpose and methods 4. patients who should have medical therapy for osteoporosis based upon 2006 Guideline for the prevention and treatment in patients osteoprosis
Exclusion criteria
Exclusion criteria: 1.rheumatic mitral valve disease 2.patients receiving treatment with oral bisphosphonates 3.congestive heart failure 4.bicuspid aortic valve 5.renal failure(eGFR<30) 6.hepatic dysfunction 7.mild aortic regurgitation, and previous aortic valve surgery 8.patients with hormone recruitment therapy 9.not suitable to this study based upon doctor's judge 10.Abnormalities of the esophagus such a achalasia 11.Known hypersensitivity to any component of this product 12.Hypocalcemia 13.Inability to stand or sit upright for at least 30 minutes after taking the medication 14.patients requiring dental treatment or within 2 month after dental treatment 15.active gastric and duodenal ulcers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of aortic valve stenosis assessed by echocardiography Left ventricular mass Clinical events or symptom | — |
Countries
Japan
Contacts
Public ContactMasao Daimon
Juntendo university School of medicine The department of cardiology
Outcome results
None listed